|Description:||1. Aristolactam AIIIa has anti-tumor activity. |
2. Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD).
3. Aristolactam IIIa shows inhibition of platelet aggregation induced by collagen or arachidonic acid.
|Targets:||CDK | MAPK|
|Source:||The herbs of Aristolochia debilis Sieb. et Zucc.|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||3.5549 mL||17.7746 mL||35.5492 mL||71.0985 mL||88.8731 mL|
|5 mM||0.711 mL||3.5549 mL||7.1098 mL||14.2197 mL||17.7746 mL|
|10 mM||0.3555 mL||1.7775 mL||3.5549 mL||7.1098 mL||8.8873 mL|
|50 mM||0.0711 mL||0.3555 mL||0.711 mL||1.422 mL||1.7775 mL|
|100 mM||0.0355 mL||0.1777 mL||0.3555 mL||0.711 mL||0.8887 mL|
Acta Pharmacol Sin. 2009 Oct;30(10):1443-53.
|The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.[Pubmed: 19801998]|
|Aristolactam AIIIa was identified as a new type of Plk1 inhibitors, targeting the Polo Box domain (PBD) which is another efficient tactic for exploring Plk1 inhibitors. Further studies indicated that it could block the proliferations of HeLa, A549, HGC and the HCT-8/V cells (clinical Navelbine-resistant cancer cell), induce mitotic arrest of HeLa cells at G2/M phase with spindle abnormalities and promote apoptosis in HeLa cells. The results from SPR and yeast two-hybrid technology-based assays suggested that it could target both the catalytic domain of Plk1 (CD) and PBD and enhance the CD/PBD interaction. CONCLUSION: Our current work is expected to shed light on the potential anti-tumor mechanism of Aristolactam AIIIa, and this natural product might be possibly used as a lead compound for further developing anti-tumor drugs.|
J Nat Prod. 2000 Aug;63(8):1160-3.
|Aristolactams and dioxoaporphines from Fissistigma balansae and Fissistigma oldhamii.[Pubmed: 10978218]|
|Investigation of extracts of Fissistigma balansae and Fissistigma oldhamii resulted in the isolation of 11 aristolactams-stigmalactam (1), piperolactam A (2), piperolactam C (3), aristolactam AII (4), Aristolactam AIIIa (5), aristolactam BII (6), aristolactam BIII (7), aristolactam FII (8), goniothalactam (9), enterocarpam I (10), and velutinam (11)-as well as two dioxoaporphines, noraristolodione (12) and norcepharadione B (13). The new compound 1 was identified by spectral data interpretation. Compounds 1-13 were subjected to antiplatelet aggregation testing.|